Aducanumab
- Generic Name
- Aducanumab
- Brand Names
- Aduhelm
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1384260-65-4
- Unique Ingredient Identifier
- 105J35OE21
- Background
Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab. Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a reduction ...
- Indication
Aducanumab is indicated for the treatment of Alzheimer’s disease. Treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were ...
- Associated Conditions
- Alzheimer's Disease (AD)
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.